INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes
Completed · Phase 4 · NCT05904743
Conditions: Diabetes Mellitus, Type 1
At a glance
- Research payments reported, 2025
- $20,630
- U.S. investigators named
- 0
- Sites paid
- 2
- Planned or actual enrollment
- 141
About the trial
- Sponsor
- Mannkind Corporation (with Jaeb Center for Health Research)
- Tested
- Afrezza (biological), insulin degludec (biological), Rapid-acting Insulin Analog (biological), Basal Insulin (biological)
- Dates
- Started 2023-07-07; completion 2024-06-24
- Results posted
- Not yet
INHALE-3 is a Phase 4, randomized controlled trial (RCT) that will randomly assign participants ≥18 years of age with type 1 diabetes (T1D) using multiple daily injections (MDI), an automated insulin delivery (AID) system, or a pump without automation, and continuous glucose monitoring (CGM) 1:1 to an insulin regimen of insulin degludec plus inhaled insulin (Afrezza) and CGM or continuation of usual care. The primary outcome of the RCT is at 17 weeks. The RCT will be followed by a 13-week extension phase in which participants in both groups will use the degludec-inhaled insulin regimen.
From ClinicalTrials.gov, last updated 2024-08-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Mannkind Corporation reported $20,630 in research payments for this study in 2025 (2 payments).
Products named: Afrezza
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.